Search

Displaying results 4231 - 4240 of 10000 in total
  1. Drug

    Gemopatrilat

    go.drugbank.com/drugs/DB20954
    Experimental

    Gemopatrilat is a small molecule drug. Gemopatrilat has a monoisotopic molecular weight of 378.16 Da.

    Categories: Agents Acting on the Renin-Angiotensin System
  2. Drug

    Moexiprilat

    go.drugbank.com/drugs/DB14210
    Experimental

    The active metabolite of the prodrug Moexipril.

    Categories: Agents Acting on the Renin-Angiotensin System
  3. Drug

    Lentinan

    go.drugbank.com/drugs/DB13480
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Deuterium oxide

    go.drugbank.com/drugs/DB19251
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Acrihellin

    go.drugbank.com/drugs/DB21069
    Experimental

    Acrihellin is a small molecule drug. Acrihellin has a monoisotopic molecular weight of 498.26 Da.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Mitemcinal

    go.drugbank.com/drugs/DB06587
    Investigational

    Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor.

  7. Drug

    Cintredekin besudotox

    go.drugbank.com/drugs/DB05305
    Investigational

    The IL13 portion binds to receptors on the tumor.

  8. Drug

    PYM50018

    go.drugbank.com/drugs/DB05126
    Experimental

    In pre-clinical models, PYM50018 has been observed to protect against neuronal damage, increase neurite outgrowth, reverse oxidative damage and reverse neuronal apoptosis in vitro.

  9. Drug

    Troxacitabine

    go.drugbank.com/drugs/DB04961
    Investigational

    There has been growing interest in its development for the treatment of patients with refractory lymphoproliferative conditions.

  10. Drug

    Barbexaclone

    go.drugbank.com/drugs/DB09001
    Experimental

    Despite the lack of controlled trials, barbexaclone was used widely in Turkey until it was discontinued in 2009. … These reports were conducted in a small series of patients in the 1970s and 1980s, and have yet to be confirmed by larger controlled trials.